Change Agents Prices a Future ELOC Before the Cash Problem Is Solved

Summary: Change Agents Corporation (CHGA) has a new AI and consumer-health narrative, but the latest filings show a company still financing basic obligations. A preliminary revised proxy filed Aug. 26 puts fourteen financing, note-conversion, forbearance, consultant-share, and charter proposals before stockholders on Oct. 8, 2026. A related Aug. 25 S-1/A registers a headline 52,235,925 shares, while one body passage prints 52,035,925, and includes a 50 million-share ELOC at a fixed $0.20 purchase price. The June 30 10-Q shows only $39,221 of cash, a $4.093 million working-capital deficit, and $3.556 million of first-half operating cash use from continuing operations. The short disagreement is not that the entire registered block is current float. It is that the market can capitalize future AI revenue and financing access while the company has almost no filed cash and a capital structure that needs shareholder approval to expand its financing path.

Scope: U.S. market, common-stock short opportunities only.

Status: Conditional Short Watchlist. The fresh proxy, resale registration, current tape, and public short-interest data are observable, but registration effectiveness, actual ELOC draws, note settlements, current post-period cash, locate, borrow, recall terms, full depth, venue quality, volume quality, and exit liquidity are not verified. The reference-only scenario map fails the Desk's 10/5 hurdle because the credible squeeze case is much wider than 5% and the gross reward-to-adverse-risk ratio is below 2:1.

Run time: 2026-08-27 22:31 Asia/Singapore. The selected market snapshot is a Nasdaq regular-session observation at 10:31 AM ET on Aug. 27, 2026. Quote time, filing time, and publication time are kept separate.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Change Agents (`CHGA`)	Short	A 50 million-share ELOC, note conversions, forbearance shares, and a charter increase are being moved toward an Oct. 8 vote, while June cash was only $39,221 and the working-capital deficit was $4.093 million.	Aug. 26 revised proxy, Aug. 25 S-1/A, Aug. 14 10-Q, Aug. 27 Nasdaq tape	Proxy vote, registration effectiveness, first ELOC draw, note settlement, and mandatory Series F redemption	226,852 shares short and 1.00 day to cover at Aug. 14; live borrow unknown	Reject for current execution; Watchlist for research	1.656 million shares traded; $0.13/$0.144 displayed market with 201/1,700 shares	The ELOC is not drawn at current prices, the vote fails, or the AI pivot creates a reflexive squeeze
2	Skye Bioscience (`SKYE`)	Short	An Aug. 24 1-for-8 reverse split repaired the displayed price, but the proposed Redx transaction leaves legacy Skye holders with only 5.38% of the combined company on the stated base case.	Aug. 20 split amendment, Aug. 14 transaction filing, June 30 10-Q	Transaction approval, financing close, and post-split registration	1,203,600 shares short and 1.51 days to cover at Aug. 14; live borrow unknown	Reject for current execution; Watchlist alternative	$1.95/$2.00 displayed market; 14,166 shares traded versus 193,240 average	$125 million of financing and a low-float post-split tape overwhelm the dilution argument
3	Tenon Medical (`TNON`)	Short	A $4.398 million ATM facility and prior warrant financing sit beside $1.7 million cash and negative operating cash, but Tenon regained Nasdaq bid-price compliance on Aug. 24.	Aug. 17 S-3/A, Aug. 13 10-Q, Aug. 24 Nasdaq compliance release	ATM sales, September equity test, and the next cash-flow filing	8,042 shares short and 1.00 day to cover at Aug. 14; live borrow unknown	Reject for current execution; Watchlist alternative	Nasdaq returned no top-of-book quote; current summary volume was only 100,566 shares	The split has already solved the nearest listing catalyst and the product ramp is real

Selected opportunity: CHGA, conditional short Watchlist.

Why this one now: CHGA has the sharpest combination of current cash stress, a fresh multi-proposal financing vote, and a registered claim ledger that contains both issued shares and future ELOC capacity. The Oct. 8 vote is close enough to be monitored but not close enough to pretend the 50 million shares are already tradable. The correct thesis is a cash and claim-state disagreement, not a claim that every number on the S-1/A is current float.

What should surprise the reader: The S-1/A has two separate data-quality problems that matter to the short thesis. Its headline and itemized components sum to 52,235,925 shares, while a cover passage says 52,035,925. Its amended ELOC terms state a fixed $0.20 purchase price, while a pro forma example still uses $0.30. Those inconsistencies do not prove fraud or selling. They do mean the claim ledger must be reconciled before any dilution arithmetic is treated as executable evidence.

Duplicate audit: The current week contains long articles on INTU, ADSK, MRVL, VTIX, ANF, DG, ZM, BOX, NTNX, BBY, CRWD, ULTA, AFRM, KSS, and BURL. VTIX was excluded as a current-week short thesis. FFAI was excluded because a July article already covers its financing and pivot. CHGA, SKYE, and TNON have no dedicated article or signal in the current-week archive.

Research query audit: I used mechanism-specific searches including revised proxy 50 million ELOC fixed purchase price shareholder approval cash deficit, registered resale component total mismatch financing claim ledger common denominator, reverse split legacy holder percentage transaction financing cash runway, and medical device ATM public float compliance operating cash. Generic earnings-only searches were not used.

Why This Is the Best Opportunity Right Now

The Aug. 26 preliminary revised proxy creates the most observable catalyst. It schedules a virtual special meeting for Oct. 8, 2026 and asks stockholders to vote on fourteen matters. The list includes the ELOC issuance, 925,925 ELOC warrant shares, future below-Minimum-Price issuances, two Vanquish note conversions, 360,000 forbearance shares, a charter increase from 100 million to 125 million authorized common shares, consultant shares, a 1 million-share pre-funded warrant, and 300,000 MFN shares. The record date is Aug. 10, when 19,646,803 common shares were outstanding and entitled to vote. CHGA Aug. 26 revised preliminary proxy

The related Aug. 25 S-1/A describes an ELOC with Hudson Global Ventures for up to $10 million of Put Shares at a fixed $0.20 purchase price, or up to 50 million shares. The company has the right, but not the obligation, to deliver Put Notices. Hudson has no right to require a sale. The registration statement and other conditions must be satisfied, and until shareholder approval the exchange cap limits purchases to about 19.99% of the relevant pre-transaction share count. CHGA Aug. 25 Form S-1/A

The cash problem is already filed. The June 30 10-Q reports $39,221 cash, $499,714 current assets, and $4,593,051 current liabilities, producing a $4,093,337 working-capital deficit. Continuing operations used $3,556,055 of operating cash in the first half. Net loss was $6,658,507, and the company states that these conditions raise substantial doubt about continuing as a going concern. CHGA June 30 Form 10-Q

The direct short setup is therefore better than a generic dilution headline. The stock has already fallen sharply, but the next repricing can be tied to a vote, registration, actual issuance, note conversion, or cash-flow filing. The strongest counterparty remains real: an approved ELOC or new financing could keep the company listed long enough for its AI products to generate revenue. That is precisely why the signal remains a Watchlist rather than an order.

Why This Can Move More Than 5% Soon

Nasdaq's Aug. 27 record shows CHGA at $0.1354, down 22.94%, with an intraday range of $0.1262 to $0.1490 and 1,655,668 shares traded. A fourteen-proposal financing vote, a new registration state, or a first Put Notice can reprice a $2.7 million provider market capitalization quickly. The current price is below the amended ELOC's fixed $0.20 purchase price, so the ELOC is not a simple current-market supply line. That makes the first actual draw and its economics more important than the 50 million-share ceiling.

The S-1/A also registers 925,925 warrant shares at a nominal $0.01 exercise price and several issued blocks from forbearance and consulting arrangements. Other disclosed claims include preferred conversions, pre-funded warrants, and Series A-1 and A-2 warrants. Those claims are not one homogeneous float. They become market supply only through the relevant approval, exercise, registration, issuance, and resale states.

The greater-than-5% move is a discovery filter. It is not a reason to short a low print, use leverage, or treat the ELOC ceiling as current selling.

10/5 Asymmetry Gate

The measurement basis is the $0.1354 reference price, not a verified executable entry. The holding window is two to eight weeks, centered on the Oct. 8 vote and the first financing or settlement disclosure. The scenario prices use the current pre-event share basis.

Favorable base move: $0.1354 to $0.0900, approximately 33.5% underlying decline.
Credible adverse move: $0.1354 to $0.2500, approximately 84.6% squeeze.
Reference-only weighted price: 0.25 x $0.0550 + 0.50 x $0.0900 + 0.25 x $0.2500 = $0.12125.
Reference-only expected short return: approximately 10.4% before borrow, fees, spread, slippage, recall, gap, and path costs.
Gross reward-to-adverse-risk: approximately 0.40:1, below the required 2:1 threshold.

10/5 status: Reject for current execution, Watchlist for research. The base decline clears the directional discovery threshold, but the credible adverse squeeze case is far beyond 5% and the entry is null. The price-only map cannot authorize a short.

What Should Surprise the Reader

The cleanest number in the filing is the 19,946,803 common shares outstanding as of Aug. 24. The least clean number is the S-1/A headline ledger. The document's itemized components sum to 52,235,925 shares, but a cover passage says 52,035,925. The pro forma example also assumes the 50 million Put Shares are sold at $0.30 even though the amended ELOC description states a fixed $0.20 purchase price. The article does not choose the convenient number. It flags both mismatches and uses the itemized ledger only as a stress map.

The state ladder is:

Current denominator: 19.946803 million common shares as of Aug. 24, subject to post-period reconciliation.
Issued resale blocks: 360,000 Agile waiver shares, 200,000 additional Agile shares, 300,000 Vision shares, and 450,000 One-Eyed Jack shares are described as issued in the S-1/A.
Conditional ELOC: up to 50 million Put Shares at $0.20, subject to Put Notices, registration, conditions, ownership limits, and the shareholder approval cap.
Conditional ELOC warrant: 925,925 shares at $0.01 after the relevant shareholder approval.
Other claims: preferred conversions, pre-funded warrants, note conversions, consultant shares, and MFN shares have distinct terms and approval states.

The key surprise is that the company can have an enormous future claim ledger and still have almost no cash today. The reverse is also true: a future financing promise can be real and still fail to provide common shareholders with usable runway.

The Setup

Change Agents changed its name from Avalon GloboCare and began trading under CHGA in July 2026. Its current business is described as two segments: an AI software segment built around the Catch-Up and Beacon products, and a consumer-health segment distributing the Keto Air breathalyzer. The S-1/A says the AI products are still being developed and that meaningful Catch-Up revenue may take approximately a year from the prospectus date. These are company expectations, not collected operating cash. CHGA Aug. 25 Form S-1/A

At June 30, CHGA had $14.721 million of total assets, but much of the non-current asset base was goodwill and intangible assets. Total liabilities were $4.649 million, and total equity was $10.071 million, a figure that includes preferred stock and non-cash accounting balances. It is not the same as unrestricted cash available to common shareholders.

The 10-Q shows no operating revenue from the current AI and consumer-health businesses sufficient to offset the cash burn. Continuing operations incurred $4.773 million of other operating expenses in the first half, including professional fees, compensation, advertising, and amortization. The company also reported a $6.555 million operating loss from continuing operations. The going-concern conclusion is not a prediction of failure, but it establishes the funding problem that the proxy is trying to solve.

The preferred and debt claims matter. Series E Preferred Stock carried a stated liquidation preference of approximately $19.396 million as of June 30 and was convertible into common stock at a stated $1.50 conversion price, subject to its terms. Series F Preferred Stock issued in July has a $400,000 stated value, a $0.50 conversion price after approval, and mandatory redemptions of 25% on each of Oct. 1, Nov. 1, Dec. 1, 2026, and Jan. 1, 2027 at 125% of stated value. That schedule implies four $125,000 cash redemption amounts if no conversion occurs, but the company's ability to fund them is not proven.

The Market Price

Metric	Value	Interpretation
Nasdaq last sale	$0.1354	Regular-session quote at 10:31 AM ET, Aug. 27, 2026
Session change	-$0.0403 / -22.94%	Sharp reaction after the new financing and approval ledger, not proof of informed selling
Intraday high / low	$0.1490 / $0.1262	Last sale was about 7.3% above the session low
Volume	1,655,668 shares	About 92% of Nasdaq's displayed 1,798,575 average volume
Displayed bid / ask	$0.1300 / $0.1440	Approximately 10.8% spread before costs
Displayed bid / ask size	201 / 1,700 shares	Top-of-book depth is not realistic exit liquidity
Provider market capitalization	$2.701 million	Context only; not reconciled to every post-period claim or preferred interest
Common shares outstanding	19,946,803	Issuer-reported as of Aug. 24, 2026
Latest public short interest	226,852 shares	Nasdaq settlement data dated Aug. 14, 2026
Days to cover	1.00	Public short-interest ratio, not live borrow availability

The Nasdaq CHGA quote snapshot supplies the last sale, session change, volume, bid, ask, and displayed sizes. The Nasdaq CHGA summary supplies the range, average volume, and provider market capitalization. The Nasdaq CHGA short-interest snapshot supplies the Aug. 14 settlement record. I do not have sufficient reliable data to quantify current borrow fee, locate availability, recall terms, full depth, venue quality, volume quality, or exit liquidity.

The Mispricing

The weak bearish argument is that 52.236 million registered shares will be sold. That claim is too strong. The ledger includes issued resale blocks, a future ELOC, a warrant that requires approval, and an internal headline inconsistency. Registration is not effectiveness, and effectiveness is not resale.

The stronger disagreement is about the difference between a financing option and usable cash. CHGA has only $39,221 of filed cash at June 30 and a $4.093 million working-capital deficit. The ELOC can provide up to $10 million in gross proceeds only if the company elects to deliver Put Notices, the registration and other conditions remain satisfied, Hudson purchases, and the transaction complies with Nasdaq limits. At the amended fixed price of $0.20, the current $0.1354 market price does not make a straightforward draw economically self-evident.

The relevant facts are:

Cash state: $39,221 at June 30.
Operating state: $3.556 million of first-half operating cash use from continuing operations.
Claim state: 19.946803 million common shares as of Aug. 24, plus issued resale blocks and conditional claims under separate terms.
Financing state: up to $10 million of ELOC proceeds, not current cash; $200,000 gross FirstFire proceeds and $550,000 gross August OID note proceeds were also disclosed in the S-1/A, with debt repayment and working capital uses.
Approval state: the Oct. 8 meeting must address the ELOC, note conversions, pre-funded warrant, forbearance shares, future issuances, and charter increase.
Data state: the S-1/A's headline and pro forma arithmetic require reconciliation before they can support a precise dilution number.

The market may be right. The vote can pass, Hudson can fund the company, creditors can accept equity or cash, and the AI products can create meaningful revenue. The market may be wrong if it prices the capital-access headline while ignoring that the cash balance and operating deficit are already current.

The Positioning

Nasdaq reports 226,852 shares short at the Aug. 14 settlement date, against average daily volume of 350,585, for 1.00 day to cover. This is not a deeply crowded short. It is a modest short base in a stock with a 10.8% displayed spread and a 22.94% same-session decline. Positioning score: 3/5.

The latest public short-interest record is stale relative to the Aug. 27 quote. Current locate availability, borrow fee, recall risk, securities-lending concentration, full order-book depth, and exit liquidity are unknown. The price and volume support an inference of fragile market structure, not proof of forced selling or a reliable supply event.

The squeeze case is asymmetric for a simple reason: a successful vote, funded ELOC, strategic AI acquisition, or note settlement that removes immediate default risk can cause buyers to compete for a narrow displayed market. The bear case should not rely on the registered ledger alone.

The Catalyst

Step	State as of this run	Cheapest test	Bearish interpretation	Squeeze or invalidation path
Oct. 8 shareholder meeting	Preliminary revised proxy filed Aug. 26; record date Aug. 10; board recommends FOR all fourteen proposals	Meeting notice, quorum, vote totals, and each proposal result	ELOC, note-conversion, warrant, forbearance, and charter capacity become authorized under their separate terms	Vote fails or is adjourned, forcing a new financing path or preserving share scarcity
ELOC registration	S-1/A filed Aug. 25; effectiveness and first Put Notice not verified	SEC effectiveness record, Put Notice, purchase amount, fixed price, and cash receipt	Hudson purchases and the company receives capital while common supply expands	No effectiveness, no Put Notice, or Hudson declines to buy at the fixed price
ELOC warrant and future claims	925,925 ELOC warrant shares plus note and pre-funded warrant proposals remain approval-dependent	Approval, exercise notice, shares issued, registration, and resale	Low-cost claims become tradable supply	Holders retain claims or Nasdaq limits prevent issuance
Current debt and preferred claims	Series F redemption schedule starts Oct. 1; FirstFire and August OID notes have future repayment terms	Cash redemption, conversion, refinancing, and post-event denominator	Senior claims absorb new financing before common equity	Debt is refinanced non-dilutively or creditors accept terms that extend runway
AI and consumer-health operations	Products are described as developing; current filing does not show meaningful operating cash	Next revenue, customer, gross-margin, cash, and operating-cash filing	Revenue remains an expectation while professional and financing costs continue	A binding customer, collected revenue, or strategic financing changes the cash bridge

The cheapest falsification sequence is the Oct. 8 vote, then S-1 effectiveness and the first ELOC purchase, then the actual cash allocation and post-draw share count, followed by the next operating-cash and preferred-redemption filing. Do not jump from registration to a full-float conclusion.

The Payoff

The short case does not require CHGA's AI products to fail. It requires the company to remain dependent on capital markets while cash, preferred claims, notes, and future share issuance compete for the same balance sheet.

The base case assumes the vote passes or is adjourned without solving the cash problem, the ELOC remains conditional or is drawn only in limited amounts, debt and preferred claims absorb new funds, and the stock tests the lower end of the current range. The top case assumes a financing, conversion, or resale state makes the claim ledger more visible before an operating cash surprise. The bottom case assumes the vote and ELOC provide a credible bridge, the AI pivot attracts buyers, and the thin displayed market creates a squeeze.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case for the short	25%	$0.0550	-59.4% underlying	2 to 8 weeks	Financing and approval claims become visible, cash remains inadequate, and no funded AI or strategic surprise appears	Medium. Cash and claim terms are filed; actual draws and resales are unknown
Base Case	50%	$0.0900	-33.5% underlying	2 to 8 weeks	Vote process continues, financing remains conditional or creditor-prioritized, and operating cash does not improve materially	Medium
Bottom Case for the short	25%	$0.2500	+84.6% squeeze	Days to 8 weeks	Vote passes, Hudson funds at or above the fixed price, creditor pressure eases, or the AI pivot creates reflexive demand	Medium-low. The funding mechanism is filed, but the commercial bridge is not proven
Invalidation	n/a	$0.3500 or higher with funded cash repair	n/a	Any time	A filed post-vote cash bridge, non-dilutive refinancing, sustained collected revenue, or an effective financing state removes the current disagreement	Medium

Probability-weighted expected value: The reference-only weighted price is $0.12125, implying approximately 10.4% expected short return before borrow, spread, slippage, recall, fees, and gap costs. Executable after-cost EV cannot be computed because entry.price is null and the short-side execution gates are incomplete.

Current market level and timestamp: $0.1354, Nasdaq regular session, 10:31 AM ET on Aug. 27, 2026.

Primary instrument: CHGA common stock only, and only after every short-side gate is independently verified.

10/5 favorable base move: 33.5% decline, reference-only.

10/5 credible adverse move: 84.6% squeeze, reference-only.

10/5 measurement basis: Reference-only, not verified entry.

10/5 status: Reject for current execution; Watchlist for research.

Confidence: Medium-low. The proxy, S-1/A, 10-Q, Nasdaq tape, and public short-interest record are auditable. The filing arithmetic mismatch, post-period cash, vote, registration, draw, settlement, borrow, and exit-liquidity states remain unresolved.

The Kill Shot

The strongest counterparty argument is that CHGA may have solved the immediate cash problem through financing access rather than operating revenue. The Oct. 8 vote could authorize the ELOC beyond the exchange cap, Hudson could purchase shares at the fixed $0.20 price, creditors could accept conversions or extensions, and the company could use the capital to launch its AI products. A stock trading below the fixed purchase price can also create a powerful headline if investors believe the ELOC is a committed backstop. The 22.94% decline may already discount much of the cash stress.

The load-bearing bearish assumption is that authorization and registration will not translate into enough usable cash before senior claims, preferred redemption, and operating burn consume the available bridge. If CHGA produces a documented cash receipt, a non-dilutive runway, or durable revenue from the AI platform, the short thesis loses its center.

What Could Go Wrong

Hudson purchases shares at $0.20 despite the lower market price, supplying cash and a financing-validation headline.
The Oct. 8 meeting approves all proposals and the charter increase, removing the nearest legal bottleneck.
The company renegotiates debt and preferred claims without meaningful common issuance.
The AI software segment signs a binding customer contract or strategic acquisition that produces a credible near-term revenue bridge.
The current short base covers into a low-float squeeze, especially if a new financing headline arrives.
A new filing corrects the S-1/A arithmetic and shows fewer effective claims than the stress ledger implies.
The stock is halted, recalled, bought in, or becomes impossible to borrow while a short is open.
The displayed bid and ask are too thin for an orderly exit, making actual losses larger than the modeled scenario.

What Would Prove This Wrong

The thesis should be removed or rebuilt if CHGA files the Oct. 8 vote results, a funded ELOC draw or non-dilutive refinancing, and a post-event cash and denominator bridge showing enough liquidity for at least twelve months without repeated discounted equity. A binding AI customer with collected revenue and positive operating cash would matter more than a product announcement.

Price alone is not enough. A move above $0.35 with fresh volume and a filed cash repair would invalidate the current price map. If the price changes because of a reverse split, recapitalization, or claim adjustment, rebuild the levels on the new share basis rather than treating the nominal move as economic proof.

Risk Audit

Risk	Current evidence	Control
Borrow and recall	Aug. 14 public short interest only; live locate, fee, and recall absent	Keep `entry.price` null and `execution.can_execute` false until a broker-level locate and borrow audit passes
Spread and depth	$0.13/$0.144 displayed market, with only 201 bid shares and 1,700 ask shares	Require fresh top-of-book, spread, full depth, venue quality, volume quality, and realistic exit liquidity
Claim-state error	S-1/A headline, component total, and pro forma example are not internally aligned	Reconcile the corrected ledger, registration effectiveness, actual issuance, first resale, cash receipt, and denominator
ELOC price risk	Fixed $0.20 purchase price is above the $0.1354 market reference	Do not assume a draw or a current supply event; verify Put Notice, closing, cash, and economics
Senior claims	Series E preference, Series F redemption, FirstFire, August OID notes, and other claims compete for cash	Track payment, conversion, refinancing, redemption, and post-event common shares in sequence
Corporate action	Fourteen proposals and a 100 million to 125 million charter amendment can change the share basis	No market order, leverage, margin, options, or short through an unverified vote or recapitalization
Operating counterparty	AI and Keto Air products may produce revenue, but meaningful current cash is not filed	Require collected revenue, gross margin, operating cash, and runway evidence
Gap and halt	Low-priced Nasdaq common with a 22.94% same-session decline	Do not rely on a 5% stop; use no trade until all execution gates pass

Best Trade Strategy

Instrument: CHGA common stock only, conditional research expression.

Entry state: entry.price = null. The Nasdaq reference quote is not a verified executable entry. Do not short the session low or infer borrow from the public short-interest record.

Conditional trigger: Reassess only after a fresh regular-session quote is not near the session low; current bid, ask, spread, depth, venue quality, volume quality, exit liquidity, locate, borrow cost, recall terms, vote state, and share-basis are independently verified; and the ELOC, note, or cash-flow filing provides a dated reason to act.

Targets: Current pre-event basis of $0.0550 top, $0.0900 base, and $0.2500 bottom. Rebuild the map after any reverse split, recapitalization, or material claim adjustment.

Invalidation: A funded non-dilutive runway, an ELOC draw that materially repairs cash without destabilizing common supply, debt settlement without common issuance, sustained collected AI revenue and positive operating cash, a binding strategic transaction, or any verified failure of locate, borrow, recall, spread, depth, venue, volume-quality, or exit-liquidity gates.

Holding window: Two to eight weeks, or until the first of the Oct. 8 vote, registration effectiveness, ELOC draw, note conversion, Series F redemption, post-event share count, or operating-cash filing materially updates the thesis.

Do not trade: Do not trade without locate and borrow confirmation. Do not use options without a verified live chain and maximum-loss model. Do not use leverage, margin, market orders, price-floor logic, or a short expression through an unverified corporate action.

Monitoring: Proxy vote and quorum; ELOC registration and Put Notices; Hudson settlement and cash receipt; note conversions and preferred redemptions; issued and resold shares; current cash and working capital; AI customer and revenue evidence; current borrow, recall, spread, depth, and exit-liquidity checks.

Sources

Source	Date or timestamp	Use
CHGA Aug. 26, 2026 revised preliminary proxy	Filed Aug. 26, 2026	Oct. 8 meeting, record date, fourteen proposals, ELOC approval, note conversions, forbearance shares, warrant, and charter increase
CHGA Aug. 25, 2026 Form S-1/A	Filed Aug. 25, 2026; prospectus dated Aug. 24	Component claim ledger, ELOC price and conditions, issued resale blocks, preferred and warrant claims, debt terms, and going-concern disclosure
CHGA June 30, 2026 Form 10-Q	Filed Aug. 14, 2026	Cash, working capital, operating cash use, losses, preferred and debt state, shares, and going-concern language
CHGA SEC submissions	Checked Aug. 27, 2026	Filing sequence and freshness
Nasdaq CHGA quote snapshot	10:31 AM ET, Aug. 27, 2026	Last sale, session change, volume, bid, ask, and displayed depth
Nasdaq CHGA summary snapshot	Aug. 27, 2026	Intraday range, average volume, and provider market capitalization
Nasdaq CHGA short-interest snapshot	Settlement date Aug. 14, 2026	Public short interest and days to cover
Skye Aug. 20 reverse-split amendment	Filed Aug. 20, 2026	Ranked alternative, split effective Aug. 24
Skye Aug. 14 transaction filing	Filed Aug. 14, 2026	Ranked alternative, Redx transaction, financing, and ownership split
Tenon Aug. 17 Form S-3/A	Filed Aug. 17, 2026	Ranked alternative, $4.398 million ATM and public-float limits
Tenon Aug. 13 Form 10-Q	Filed Aug. 13, 2026	Ranked alternative, cash, revenue, operating cash, and listing state
Tenon Nasdaq compliance release	Published Aug. 24, 2026	Ranked alternative, bid-price compliance resolved

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	4/5	Future financing and AI optionality conflict with current cash and senior-claim pressure
Evidence base	5/5	Fresh proxy and S-1/A, latest 10-Q, exchange quote, and public short-interest data
Positioning and flows	3/5	Public short interest is direct, but live borrow, recall, full depth, and flow data are missing
Catalyst path	4/5	Vote, registration, ELOC draw, note settlement, redemption, and cash filing are observable
Payoff architecture	3/5	Reference-only expected return is positive, but the squeeze case fails the 10/5 bound and 2:1 ratio
Invalidation discipline	4/5	Funded runway, draw economics, debt settlement, operating cash, and gate failures are explicit
Differentiated insight	4/5	Surfaces the internal claim-ledger mismatch and separates fixed-price ELOC capacity from current supply
Client value	4/5	The piece gives a useful vote-to-cash monitoring sequence even without a trade
Total	31/40	Watchlist range; execution remains blocked

Classification: Watchlist for research, Reject for current execution. A score cannot override the failed 10/5 hurdle or missing short-side gates.

Bottom Line

CHGA may eventually build a valuable AI product, but the latest filings describe a company that needs the capital market before the operating business can prove itself. The Oct. 8 vote matters because it can authorize several future claim states. It does not itself create cash, revenue, or common-stock value. The next useful facts are the vote result, S-1 effectiveness, first ELOC draw, actual cash allocation, note and preferred settlement, post-event denominator, and operating-cash filing. Until those facts and borrow conditions are verified, the correct state is Watchlist, no trade.

AI Illustration Prompt

Create a realistic, high-end editorial cover illustration for The Mispricing Desk about Change Agents Corporation and a future ELOC arriving before cash repair. Stage a quiet institutional filing room that blends a modest AI software lab with a worn corporate finance desk. In the foreground, place a brushed-metal claim ledger with two conflicting handwritten totals, 52,235,925 and 52,035,925, visibly separated by a fine red correction mark. Beside it, place a sealed financing folder labeled $10m ELOC at $0.20, an Oct. 8 virtual shareholder-meeting card marked 14 proposals, and a nearly empty cash envelope marked $39,221. On the opposite side of the table, show distinct senior-claim folders labeled Series E, Series F redemption, FirstFire, and note conversions, with a narrow stream of future share certificates flowing toward them before reaching a dim common-stock tray. In the background, show a small AI interface prototype and a Keto Air breathalyzer, both real and understated, suggesting genuine product optionality without pretending it is current cash. Use graphite, midnight navy, brushed aluminum, warm paper white, muted teal, and one restrained warning red. Mood: forensic, calm, premium, slightly tense. Style: Bloomberg Markets or Barron's cover realism, physically believable materials, no generic stock chart, no neon, no traders, no cash rain, no hype. Include a subtle but clearly readable watermark or etched text reading The Mispricing Desk.